ArticleCureus2025
Combination Therapy With Ensitrelvir and Remdesivir Versus Antiviral Monotherapy in Patients Receiving Anti-CD20 Monoclonal Antibody Therapy: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background We aimed to evaluate the effectiveness of combination therapy with ensitrelvir and remdesivir compared to antiviral monotherapy in patients with a history of anti-CD20 monoclonal antibody therapy who were hospitalized with COVID-19. Methods This retrospective cohort study was conducted at St. Marianna University Hospital (a tertiary care hospital) in Kawasaki, Kanagawa, Japan. Among 1,549 patients hospitalized with COVID-19 between April 2022 and December 2024, 17 patients with a history of anti-CD20 monoclonal antibody therapy were included in the study. Among them, seven patients received combination therapy (ensitrelvir and remdesivir), and 10 received antiviral monotherapy. Ensitrelvir and remdesivir were administered for five and five to 10 days, respectively. Results No deaths occurred within 30 days. The one-year mortality rate was significantly lower in the combination group (1/7, 14.3%) than in the monotherapy group (7/9, 77.8%; p = 0.041). Case 8 was excluded from this analysis due to insufficient follow-up duration. At baseline, the combination therapy group had a higher proportion of patients with severe or critical COVID-19 (6/7, 85.7% vs. 2/10, 20.0%), a lower median serum IgG level (526 vs. 908.5 mg/dL), and a higher prevalence of pneumonia (6/7, 85.7% vs. 2/10, 40.0%). Despite these more severe baseline characteristics, the combination therapy group showed significantly lower post-treatment antigen levels (median (IQR): 11.24 pg/mL (1.76-49.39 pg/mL) vs. 2792.41 pg/mL (186.9-5000 pg/mL), p = 0.0303). Conclusions Combination therapy with ensitrelvir and remdesivir was associated with lower long-term mortality and viral burden in patients with COVID-19 who had received anti-CD20 monoclonal antibody therapy. However, these results are based on a small retrospective cohort and should be interpreted as hypothesis-generating; larger prospective studies are needed to determine whether this association reflects a true therapeutic effect.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.